Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Mayo Clin Proc. 2019 Jun 24;94(10):2011–2021. doi: 10.1016/j.mayocp.2019.05.022

Table 3.

Indications for 600 CTs among 200 patients with high estimated cumulative radiation exposure (≥100 mSv/10 years).

Proportion of CTs
Positive resulta
n % (95% CI) n % OR (95% CI)
1 Restaging of solid cancer 110 18.3% (14.9 – 21.8%) 20 18.2% 0.34 (0.17–0.65)
2 Abdominal pain 103 17.2% (13.8 – 20.5%) 33 32.0% 0.79 (0.44–1.43)
3 Lymphoma restaging 73 12.2% (9.4 – 15.0%) 11 15.1% 0.24 (0.10–0.56)
4 Infection 42 7.0% (4.9 – 9.1%) 22 52.4% 2.06 (0.94–4.51)
5 All otherb 36 6.0% (4.0 – 8.0%) 12 33.3% Referencec
6 Nephrolithiasis workup 34 5.7% (3.8 – 7.6%) 17 50.0% 1.59 (0.68–3.72)
7 Nodule/mass follow up 31 5.2% (3.3 – 7.0%) 8 22.6% 0.50 (0.18–1.39)
8 Chest pain/pulmonary embolism rule-out 30 5.0% (3.2 – 6.8%) 2 6.7% 0.10 (0.02–0.47)
9 Initial workup for/of cancer 23 3.8% (2.3 – 5.4%) 15 65.2% Referencec
10 Vascular restaging 23 3.8% (2.3 – 5.4%) 9 39.1%   graphic file with name nihms-1531307-t0003.jpg
11 Motor vehicle accident 16 2.7% (1.4 – 4.0%) 5 31.3%
12 Headache 13 2.2% (1.0 – 3.3%) 1 7.7%
13 Fall 12 2.0% (0.9 – 3.1%) 2 16.7%
14 Trauma (other than motor vehicle accident, fall) 12 2.0% (0.9 – 3.1%) 6 50.0%
15 Activity of inflammatory bowel disease 10 1.7% (0.6 – 2.7%) 5 50.0%
16 Painless hematuria 9 1.5% (0.5 – 2.5%) 5 55.6%
17 Stroke 7 1.2% (0.3 – 2.0%) 2 28.6%
18 Altered mental status 5 0.8% (0.1 – 1.6%) 0 0%
19 Back pain, nontraumatic 4 0.7% (0.0 – 1.3%) 1 25.0%
20 Hemorrhage (other than hematuria, stroke) 4 0.7% (0.0 – 1.3%) 2 50.0%
21 Pain (other than headache, chest, abdominal) 2 0.3% (0.0 – 0.8%) 1 50.0% Referencec
22 Unclear (unable to tell from medical record) 1 0.2% (0.0 – 0.5%) Unknown Unknown

600 100% 178 29.7%
a

Positive results are defined as results related to the main indication, or major findings that would necessitate timely changes in plan of care. Odds ratios assess how common positive results are among specific “top” indications compared to the remainder of the indications, accounting for within-patient correlation between the three CTs per patient.

b

The category “all other” contains all indications not described by the 21 listed indications.

c

Indications with fewer than 30 CTs (ranks 9–22) and “All other” served as the reference category for comparisons of positivity.